SomaLogic, Inc.
SLGC · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.67 | -0.30 | -1.36 | 0.00 |
| FCF Yield | -22.93% | -2.74% | -1.18% | -2.04% |
| EV / EBITDA | -0.24 | -15.78 | -75.40 | -52.13 |
| Quality | ||||
| ROIC | -28.79% | -10.68% | -20.38% | -90.08% |
| Gross Margin | 55.60% | 59.00% | 59.54% | -54.47% |
| Cash Conversion Ratio | 0.92 | 0.42 | 0.53 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.45% | 36.37% | 3,823,232.89% | 3,180,874.35% |
| Free Cash Flow Growth | -142.29% | -48.16% | 42.41% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 2.39 | 5.99 | 4.07 | 0.29 |
| Interest Coverage | 0.00 | -55.37 | -1.87 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.12 | 2.98 | 3.22 | 5.90 |
| Cash Conversion Cycle | 39.17 | 34.07 | 113.25 | 87.38 |